SELLAS Life Sciences (SLS) Cash from Operations Growth (5y) (2015 - 2026)
SELLAS Life Sciences (SLS) Cash from Operations Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn |
| 10 | SELLAS Life Sciences | 1.88 Bn | 1.77 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.04% |
| Dec 31, 2025 | -28.03% |
| Sep 30, 2025 | -14.26% |
| Jun 30, 2025 | -16.74% |
| Mar 31, 2025 | -5.83% |
| Dec 31, 2024 | -11.36% |
| Sep 30, 2024 | -15.36% |
| Jun 30, 2024 | -15.77% |
| Mar 31, 2024 | -16.61% |
| Dec 31, 2023 | -1.16% |
| Sep 30, 2023 | 13.42% |
| Jun 30, 2023 | -3.73% |
| Mar 31, 2023 | -17.55% |
| Dec 31, 2022 | -24.22% |
| Sep 30, 2022 | -19.13% |
| Jun 30, 2022 | -13.57% |
| Mar 31, 2022 | -13.46% |
| Dec 31, 2021 | -18.26% |
| Sep 30, 2021 | -14.00% |
| Jun 30, 2021 | 20.02% |